A Highly Effective Component Vaccine against Nontyphoidal <named-content content-type="genus-species">Salmonella enterica</named-content> Infections
Rosana B. R. Ferreira,
Yanet Valdez,
Brian K. Coombes,
Subash Sad,
Joost W. Gouw,
Eric M. Brown,
Yuling Li,
Guntram A. Grassl,
L. Caetano M. Antunes,
Navkiran Gill,
Mimi Truong,
Roland Scholz,
Lisa A. Reynolds,
Laskshmi Krishnan,
Ahmed A. Zafer,
Neta Sal-Man,
Michael J. Lowden,
Sigrid D. Auweter,
Leonard J. Foster,
B. Brett Finlay
Affiliations
Rosana B. R. Ferreira
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Yanet Valdez
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Brian K. Coombes
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Subash Sad
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
Joost W. Gouw
Centre for High-Throughput Biology and Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, British Columbia, Canada
Eric M. Brown
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Yuling Li
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Guntram A. Grassl
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
L. Caetano M. Antunes
Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
Navkiran Gill
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Mimi Truong
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Roland Scholz
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Lisa A. Reynolds
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Laskshmi Krishnan
National Research Council Canada, Institute for Biological Sciences, Ottawa, Ontario, Canada
Ahmed A. Zafer
National Research Council Canada, Institute for Biological Sciences, Ottawa, Ontario, Canada
Neta Sal-Man
Departament of Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
Michael J. Lowden
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Sigrid D. Auweter
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
Leonard J. Foster
Centre for High-Throughput Biology and Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, British Columbia, Canada
B. Brett Finlay
Michael Smith Laboratories, The University of British Columbia, Vancouver, British Columbia, Canada
ABSTRACT Nontyphoidal Salmonella enterica (NTS) infections are a major burden to global public health, as they lead to diseases ranging from gastroenteritis to systemic infections and there is currently no vaccine available. Here, we describe a highly effective component vaccine against S. enterica serovar Typhimurium in both gastroenteritis and systemic murine infection models. We devised an approach to generate supernatants of S. enterica serovar Typhimurium, an organism that is highly abundant in virulence factors. Immunization of mice with this supernatant resulted in dramatic protection against a challenge with serovar Typhimurium, showing increased survival in the systemic model and decreased intestinal pathology in the gastrointestinal model. Protection correlated with specific IgA and IgG levels in the serum and specific secretory IgA levels in the feces of immunized mice. Initial characterization of the protective antigens in the bacterial culture supernatants revealed a subset of antigens that exhibited remarkable stability, a highly desirable characteristic of an effective vaccine to be used under suboptimal environmental conditions in developing countries. We were able to purify a subset of the peptides present in the supernatants and show their potential for immunization of mice against serovar Typhimurium resulting in a decreased level of colonization. This component vaccine shows promise with regard to protecting against NTS, and further work should significantly help to establish vaccines against these prevalent infections. IMPORTANCE Salmonella enterica infections other than typhoid and paratyphoid fever are a major global health burden, as they cause high morbidity and mortality worldwide. Strategies that prevent Salmonella-related diseases are greatly needed, and there is a significant push for the development of vaccines against nontyphoidal Salmonella enterica serovars. In this work, we describe an S. Typhimurium supernatant-derived vaccine that is effective in reducing bacterial colonization in mouse models of gastroenteritis as well as invasive disease. This is a component vaccine that shows high stability to heat, a feature that is important for use under suboptimal conditions, such as those found in sub-Saharan Africa.